Subject: Re: Drugs for Hep C program-Georgia
From: "Averhoff, Francisco (CDC/DDID/NCHHSTP/DVH)" <[email-masked]>
To: Tamar Gabunia <[email-masked]>
Cc: Ekaterine Adamia <[email-masked]>, Irinka Tskhomelidze <[email-masked]>, Tatia Kuchuloria <[email-masked]>, "Koscelski, Anna (CDC/DDID/NCHHSTP/DVH)" <[email-masked]>
Date: Tue, 03 Sep 2019 12:31:26 +0000

Dear Tamar, I would be very happy to participate in a discussion. Would next week be ok? Or could do this week as well, please advise, I am including Anna who knows my calendar well, and I can be flexible, best FA

Get Outlook for iOS

From: Tamar Gabunia <[email-masked]>

Sent: Tuesday, September 3, 2019 7:51:06 AM

To: Averhoff, Francisco (CDC/DDID/NCHHSTP/DVH) <[email-masked]>

Cc: Ekaterine Adamia <[email-masked]>; Irinka Tskhomelidze <[email-masked]>; Tatia Kuchuloria <[email-masked]>

Subject: Drugs for Hep C program-Georgia

Dear Francisco

I hope this e-mail will find you doing well. I am writing to ask for your advice on the following. As you may know we are in the process of developing the next year forecast for Hep C drugs. The National program leaders consider both options
(1) full transition to Epclusa only regimen and (2) use Harvoni for genotype 1 patients and Epclusa for 2 and 3 as it is right now. The latter is the preferred option for the clinical team here. However, Dr Tengiz and others are willing to discuss more pros
and cons of both options. Would you mind to assist with this discussion and facilitate decision making. We could have a conference call at your convenience sometime soon.

Many thanks and looking forward.

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

Sincerely,

Tamar Gabunia,
MD, MPH

Deputy Minister